Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Vincamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 3/20 | 0.98 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.98 |
| ▸ | PDE4D known ✓ | Q08499 | 2/20 | 0.77 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 2/20 | 0.77 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.77 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.50 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.50 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.50 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.50 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.50 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.50 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.98 |
| ▸ | MEN1 | O00255 | 3/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.98 |
| ▸ | MAPT | P10636 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vincamine SCHEMBL30892136 | 0.99 | CYP3A4 (1.00) | CYP3A4KCNH2CYP2D6HIF1AMEN1 | |
| Vincamine SCHEMBL3767 | 0.99 | CYP3A4 (1.00) | CYP3A4KCNH2CYP2D6HIF1AMEN1 | |
| Vincamine SCHEMBL29710919 | 0.99 | CYP3A4 (1.00) | CYP3A4KCNH2CYP2D6HIF1AMEN1 | |
| Vincamine SCHEMBL147179 | 0.99 | CYP3A4 (1.00) | CYP3A4KCNH2CYP2D6HIF1AMEN1 | |
| Vincamine SCHEMBL8970683 | 0.99 | CYP3A4 (1.00) | CYP3A4KCNH2CYP2D6HIF1AMEN1 | |
| Vincamine SCHEMBL14095103 | 0.99 | CYP3A4 (1.00) | CYP3A4KCNH2CYP2D6HIF1AMEN1 | |
| Vincamine SCHEMBL6631357 | 0.97 | CYP3A4 (0.96) | CYP3A4KCNH2CYP2D6HIF1AMEN1 | |
| Vincamine SCHEMBL5712113 | 0.97 | CYP3A4 (0.96) | CYP3A4KCNH2CYP2D6HIF1AMEN1 | |
| Vincamine SCHEMBL6162410 | 0.96 | CYP3A4 (0.95) | CYP3A4KCNH2CYP2D6HIF1AMEN1 | |
| Vincamine SCHEMBL11619815 | 0.96 | CYP3A4 (0.93) | CYP3A4KCNH2CYP2D6HIF1AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4369175-A | Process for the manufacture of prolonged action vincamine preparations, the vincamine preparations so obtained, and medicaments containing them | CIBA-GEIGY CORPORATION (US) | 1983-01-18 | — | — | US | claimed |
| CN-113754768-B | Antibodies that bind CD39 and uses thereof | 表面肿瘤学公司 | 2023-01-06 | — | — | CN | disclosed |
| CN-113444086-A | Ezh2 inhibitor and application thereof | 达纳-法伯癌症研究所股份有限公司 | 2021-09-28 | — | — | CN | disclosed |
| CN-113164477-A | Pyrazolopyridine inhibitors of C-JUN-N-terminal kinase and uses thereof | 达纳-法伯癌症研究所股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-106029696-B | anti-CD 3 antibodies and methods of use | 基因泰克公司 | 2020-07-28 | — | — | CN | disclosed |
| EP-0573260-B1 | New alkaloid derivatives, their use and pharmaceutical formulations containing them | INDENA SPA (IT) | 2000-05-10 | — | — | EP | disclosed |
| US-4431641-A | AN ANTICONVULSANT DIBENZ/B,F/AZEPINE POTENTIATED BY A VINCAMINE OR PIRACETAM DERIVATIVE | CIBA-GEIGY CORPORATION (US) | 1984-02-14 | — | — | US | disclosed |
| US-4369175-A | Process for the manufacture of prolonged action vincamine preparations, the vincamine preparations so obtained, and medicaments containing them | CIBA-GEIGY CORPORATION (US) | 1983-01-18 | — | — | US | disclosed |
| US-4199585-A | ADMINISTERING VINCAMINE | INSTITUTO CHEMIOTERAPICO DI LODI SPA, A CORP OF ITALY (IT) | 1980-04-22 | — | — | US | disclosed |
| US-4178695-A | BY FREEZE DRYING WITH CONTROLLED COOLING UNDER AGITATION TO PRODUCE MICROCRYSTALS | ERBEIA ANGELO (FR) | 1979-12-18 | — | — | US | disclosed |
| US-4140777-A | Cerebral vasodilating 6-substituted vincamines | ENRICO CORVI MORA (IT) | 1979-02-20 | — | — | US | disclosed |
| US-4122179-A | VASODILATORS | Mora, Enrico Corvi (IT) | 1978-10-24 | — | — | US | disclosed |
| US-3982002-A | VASODILATOR, BRAIN OXYGENATOR | ESPECIALIDADES LATINAS MEDICAMENTOS UNIVERSALES S.A. (ES) | 1976-09-21 | — | — | US | disclosed |